2024
632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Lin C, Schneider R, Gutierrez M, Shen L, Chung K, Doroshow D, Gao B, Millward M, Hsieh C, Xu C, Cai S, Tian Y, Liu L, Shen C, Tan Y, He Y, Zhang C, Li L, Ma M, Xu L. 632P Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors. Annals Of Oncology 2024, 35: s503-s504. DOI: 10.1016/j.annonc.2024.08.699.Peer-Reviewed Original ResearchC-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis
Fujiwara Y, Karol A, Joshi H, Reford E, Izadmehr S, Doroshow D, Galsky M. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology 2024, 197: 104352. PMID: 38614269, PMCID: PMC11219184, DOI: 10.1016/j.critrevonc.2024.104352.Peer-Reviewed Original ResearchConceptsProgression-free survivalC-reactive proteinUrothelial carcinomaTumor-promoting inflammationOverall survivalCRP valuesHazard ratioPro-inflammatory tumor microenvironmentAssociated with shorter OSICB-treated patientsImmune checkpoint blockadeEvaluate survival outcomesRandom-effects model meta-analysesHigher CRP levelsSystematic reviewMeta-analysesLow CRP valuesCheckpoint blockadeShorter OSSurvival outcomesTumor microenvironmentCRP levelsPrognostic biomarkerCarcinomaPatients
2023
EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer
Desland F, Fitzgerald B, Sheppard R, Van Hyfte G, Shimkus M, Rohs N, Veluswamy R, Rolfo C, Marron T, Smith C, Gomez J, Doroshow D. EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2023, 18: s644. DOI: 10.1016/j.jtho.2023.09.1225.Peer-Reviewed Original ResearchcfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations
Peleg A, Del Re M, Raphael A, Wang X, Berkovich A, Tsuriel S, Lichtman S, Elias E, Gomez J, Doroshow D, Smith C, Veluswamy R, Marron T, Rohs N, Mack P, Hirsch F, Rolfo C. cfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations. The Journal Of Liquid Biopsy 2023, 1: 100047. DOI: 10.1016/j.jlb.2023.100047.Peer-Reviewed Original Research
2006
Performing a Cure for Schizophrenia: Insulin Coma Therapy on the Wards
Doroshow DB. Performing a Cure for Schizophrenia: Insulin Coma Therapy on the Wards. Journal Of The History Of Medicine And Allied Sciences 2006, 62: 213-243. PMID: 17105748, DOI: 10.1093/jhmas/jrl044.Peer-Reviewed Original ResearchConceptsInsulin coma therapyComa therapyInsulin unitsMental illnessTreatment of diabetesIntractable patientsRisk assessment testsEfficacious treatmentSide effectsSomatic therapiesTherapyMental hospitalsMiracle drugTreatmentMainstream medicineIllnessMedical doctorsPsychiatristsSchizophreniaBiological psychiatryModern biological psychiatryPsychiatryComplicationsPatientsDiabetes